DLL3: an emerging target in small cell lung cancer

DLL3: an emerging target in small cell lung cancer

Abstract Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. Despite high rates of response to first-line chemotherapy and radiotherapy, patients with extensive-stage disease eventually relapse, and very few patients survive more than 5 years from diagnosis. Treatment o...

Full description

Bibliographic Details
Main Authors: Dwight H. Owen, Michael J. Giffin, Julie M. Bailis, Marie-Anne Damiette Smit, David P. Carbone, Kai He
Format: Article
Language:English
Published: BMC 2019-06-01
Series:Journal of Hematology & Oncology
Subjects:
Antibody-drug conjugate (ADC)
Bispecific T cell engager (BiTE®) antibody construct
Chimeric antigen receptor (CAR) T cell therapy
Delta-like ligand 3 (DLL3)
Immuno-oncology therapy
Neuroendocrine
Online Access:http://link.springer.com/article/10.1186/s13045-019-0745-2

Internet

http://link.springer.com/article/10.1186/s13045-019-0745-2

Similar Items